CPT code 92557: Comprehensive audiometry billing guide (2026)
CPT code 92557: Definition and clinical description CPT code 92557 covers compre...
Last Updated: September 3, 2026
Key takeaways
HCPCS Code J0710 is the deleted Level II code for injection of cephapirin sodium, up to 1 gram, given parenterally.
The code is no longer active for billing. Claims filed under J0710 for current dates of service are denied by Medicare and most payers.
J3490 is the primary crosswalk for cephapirin sodium, and it needs a drug narrative covering dose, route and NDC.
Practice management software like Pabau submits claims electronically, checks required fields before submission, and tracks each claim through five status stages.
HCPCS Code J0710 is a deleted Level II code that described injection of cephapirin sodium, up to 1 gram. It is no longer valid on current dates of service, so any claim filed under it comes back denied. Practices that still administer the drug bill it under J3490, the unclassified drug code.
This guide covers the original descriptor, why CMS retired the code, and the crosswalk that replaced it. It also sets out Medicare’s payment treatment and a six-step submission workflow for current claims.
Found our content helpful?
HCPCS Code J0710: definition and code details
HCPCS Code J0710 is a Level II National Code maintained by CMS under the HCPCS code set. The official descriptor reads: Injection, cephapirin sodium, up to 1 gm. It sits in the J-series, which covers drugs given by injection in physician office and outpatient settings under Medicare Part B.
Cephapirin sodium is a first-generation cephalosporin antibiotic. The beta-lactam compound is given parenterally, either intravenously or intramuscularly. It treated serious bacterial infections in settings where oral antibiotics were not an option. The billing unit of up to 1 gram set the threshold per administration, so doses above 1 gram took multiple units.
Why the code was deleted
HCPCS Code J0710 carries a deleted status in the CMS code file. Deleted means the code is no longer recognized for billing on current dates of service.
The HCPCS National Panel retires a J-series drug code for one of three reasons:
- The drug is withdrawn from the US market.
- Its commercial availability falls below the threshold for keeping a dedicated code.
- CMS consolidates the drug into an existing unclassified code category.
Cephapirin sodium’s limited market presence in the United States is why J0710 was retired. The drug is not widely available for physician office or outpatient use. That removed the need for a dedicated billing code.
One nuance matters for older encounters. If a claim carries a date of service from when J0710 was still active, some payers may still process the original code. MAC guidance varies here. Verify with your Medicare Administrative Contractor before you submit a retroactive claim under a deleted code.
Pro Tip
Check your MAC’s Local Coverage Determination (LCD) bulletin archive before submitting any retroactive claim under a deleted J-code. CGS Medicare, Noridian, and Palmetto GBA each publish quarterly code update bulletins that confirm which codes were active during specific date-of-service windows.
Crosswalk and replacement codes
When a dedicated J-code is deleted, CMS routes claims through the unclassified drug code. J3490 covers any injectable drug with no assigned HCPCS code. It is not tied to one product, so the payer has to be told what was given.
Three routes cover almost every cephapirin sodium claim, and the date of service picks between them.
Payer acceptance of J3490 is not automatic. Most Medicare Administrative Contractors and commercial payers require supporting documentation when an unclassified code is submitted.
That documentation names the drug, the dosage, and the route of administration. It goes on the claim itself or travels as an attachment. Without it, the claim is held for additional development or denied.
When using J3490, AAPC coding guidance recommends a narrative description in Box 19 of the CMS-1500 form. The equivalent field in your 837P transaction does the same job. The narrative should state the drug name, the strength administered, the route, and the NDC number where available. Omitting any of these raises the chance of a medical review request.
Medicare billing rules for J0710
Under Medicare Part B, injectable drugs given in outpatient settings and physician offices are paid on Average Sales Price (ASP). A percentage add-on sits on top of that. J0710 is deleted, so no current Medicare rate is attached to it. The CMS ASP drug pricing files list rates for active J-codes only.
For claims submitted under J3490 as the crosswalk, Medicare payment is settled through individual payer review. Unclassified drug codes carry no assigned ASP rate, so the payer assesses cost from invoice or acquisition documentation. Keep acquisition cost invoices ready to submit alongside the claim.
Place of service matters too. Medicare Part B drug administration coverage differs by setting. Physician office (POS 11) and outpatient hospital (POS 22) claims run on distinct payment methodologies. Verify the POS code before submission, since a mismatch with the administered drug’s billing code is a common denial trigger.
Expect remittance advice on J3490 claims to carry remark codes about additional documentation or manual pricing review. Build a step into your billing process that flags these claims for follow-up within 30 days. The denial patterns for unclassified codes are predictable, which makes them correctable.
How to bill cephapirin sodium after J0710 deletion
Practices that still administer cephapirin sodium need a settled billing workflow. The six steps below follow CMS policy for deleted drug J-codes. MAC guidance on unclassified drug billing fills in the documentation detail.
- Verify drug availability and clinical indication. Confirm cephapirin sodium is available through your supplier, and that the administration is documented in the patient record. Without a clinical rationale tied to a covered ICD-10 diagnosis code, the claim will not survive payer review.
- Select J3490 as the billing code. J3490 is the code for cephapirin sodium on current dates of service. J0710 never belongs on a current encounter. Confirm the code is still active using the NLM HCPCS Level II lookup API or your billing software’s validation tool.
- Document the drug specifics in the claim narrative. Box 19 of the CMS-1500 form takes the drug name, dose, route, frequency, and NDC number. The equivalent 837P loop takes the same five items. A charge sheet that already captures them keeps the narrative consistent from encounter to claim.
- Attach acquisition cost documentation. Medicare and many commercial payers may ask for an invoice showing what your practice paid for the drug. Prepare it before you submit, so an additional development request does not stall the claim.
- Submit a clean claim and monitor the remittance. Track the claim through the ERA/835 cycle after submission. Flag any denial or remark code that points to missing documentation or pricing under review. Clearinghouse submission catches formatting errors before the claim reaches the payer.
- Appeal denials with supporting documentation. Read the denial reason code first. Most denials on unclassified drug codes clear once you appeal with the narrative description and the acquisition cost invoice. Incomplete documentation, rather than the crosswalk itself, causes the majority of them.
The clinical record has to support the claim before it goes out. The note should carry the drug name, dose, route, time administered, and the practitioner’s signature. Payers auditing J3490 claims routinely pull medical records to check those details.
Pro Tip
Build a J3490 billing checklist in your billing workflow: drug name confirmed, dose and route noted, NDC documented, acquisition invoice attached, ICD-10 diagnosis code linked. Claims that carry all five elements draw far fewer additional development requests.
Related HCPCS J-codes for antibiotic injections
Several injectable antibiotics have carried dedicated HCPCS codes over the years. The table below lists the ones closest to cephapirin sodium, with their current status. Check status in our HCPCS code index before you submit any J-code claim, because a code that was active last year may not be now.
First-generation cephalosporins like cefazolin kept their codes because they remain in widespread clinical use. Cephapirin sodium’s limited availability is what drove J0710’s deletion. If you are substituting a more available antibiotic in the same class, check for its own active code first. Defaulting to J3490 costs you documentation work you may not need.
How Pabau keeps unclassified drug claims moving
Billing an unclassified code by hand means one person holding the narrative requirements in their head. The drug name, dose, route and NDC have to reach the claim every time. A missing field usually surfaces only after the payer sends the claim back.
Practice management software like Pabau moves those checks earlier. Pabau’s claims management software validates required fields in the background before a claim goes out. Incomplete claims get caught at your desk rather than at the payer’s.
Each submitted claim then moves through five status stages. Your team can see where a J3490 claim is sitting without calling the payer. When remittance comes back, it lands against the same patient record that holds the encounter.
Submit claims and see where each one stands
Pabau’s claims management software submits claims electronically, checks required fields in the background, and tracks every claim through five status stages. See it in action.
Conclusion
J0710 is retired, and putting it on a current claim guarantees a denial. J3490 is the way forward, paired with a complete drug narrative. Where the payer asks, add an acquisition cost invoice. What decides whether those claims pay is documentation discipline, not the crosswalk.
Set the checklist once and the denials stop being a surprise. That matters most for teams handling several unclassified drug codes across a busy outpatient schedule. Book a demo to see how Pabau tracks each claim from submission to remittance.
Continue your research
Need to understand how claims move through payers? Medical claims clearinghouse explained covers how electronic claims are validated and routed before reaching the payer.
Seeing repeated denials on drug injection claims? What makes a clean claim outlines the documentation and formatting requirements that reduce denial rates on first submission.
Want to improve billing accuracy across your team? Best medical billing software for US practices compares the tools that handle code management, claim tracking, and remittance workflows.
Frequently asked questions
What is HCPCS Code J0710?
HCPCS Code J0710 is a deleted Level II code that described injection of cephapirin sodium, up to 1 gram. It billed Medicare Part B and commercial payers for parenteral administration of a first-generation cephalosporin antibiotic. The code is no longer active and cannot be used on current dates of service.
What is the replacement code for J0710?
J3490 (unclassified drugs) is the primary replacement code for billing cephapirin sodium after J0710 was deleted. Submitting J3490 requires including the drug name, dose, route, and NDC number in the claim narrative. Some payers also require acquisition cost documentation before processing payment.
Is HCPCS Code J0710 still active?
No. HCPCS Code J0710 is deleted and inactive. Claims submitted under J0710 for current dates of service will be denied by Medicare and most commercial payers. For retroactive claims with a date of service from when the code was active, check with your MAC before submitting under the original code.
How do you bill for cephapirin sodium if J0710 is deleted?
Bill cephapirin sodium using J3490, the unclassified drug code, with a complete narrative description in Box 19 of the CMS-1500. The equivalent 837P field does the same job on an electronic claim. The narrative must include the drug name, dose, route of administration, and NDC number. Attach acquisition cost invoices if the payer requests them during claim review.
What did J0710 Medicare billing look like before deletion?
Before deletion, J0710 was paid under Medicare Part B at an ASP-based rate, typically ASP plus a percentage add-on. That applied in outpatient and physician office settings. Claims required a supporting ICD-10 diagnosis code and documentation of the drug administration in the patient record. No current Medicare reimbursement rate exists for J0710.
How does J0710 relate to J3490 for unclassified drugs?
J3490 is the billing fallback for any injectable drug that lacks a dedicated HCPCS code, including drugs whose codes have been deleted. When J0710 was active, it gave cephapirin sodium a specific code. After deletion, J3490 became the right code, but it needs more documentation than a drug-specific J-code. Payers must review pricing manually rather than apply a standard ASP rate.
Found our content helpful?
